Bioequivalence Study of a Fixed-Dose Combination of Bempedoic Acid, Ezetimibe, and Atorvastatin Versus Individual Tablet Formulations

The primary objective of this study is to evaluate the **bioequivalence** of a fixed-dose combination of Bempedoic Acid/Ezetimibe and Atorvastatin compared to the individual administration of these tablets. This assessment is clinically relevant as it may offer insights into the potential for simplified dosing regimens, which could enhance patient adherence and optimize therapeutic outcomes in managing lipid levels. No secondary objectives are specified for this study.

The clinical trial involves a **study population** that includes both male and female participants, with an age range categorized as 3, which typically corresponds to adults. The trial population is noted to include a **vulnerable population**, although specific details regarding the nature of this vulnerability are not provided. The sponsor has not disclosed the total number of participants involved in the study. Participants were selected without any specific medical condition being a requirement, as indicated by the absence of a defined medical condition for inclusion. Lifestyle considerations such as diet, physical activity, or habits have not been specified. The sponsor has not provided detailed information regarding key inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the **bioequivalence** of a fixed-dose combination of Bempedoic Acid, Ezetimibe, and Atorvastatin compared to individual tablets. This study is a Phase 2 trial, which is categorized as a randomized, double-blind, controlled trial. The estimated recruitment start date is December 8, 2025, with an anticipated end date of March 3, 2026. The trial does not focus on any specific medical condition, as indicated by the absence of a targeted disease.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into different study arms. The trial will include multiple follow-up visits to monitor the participants' response to the treatment and ensure adherence to the study protocol. The end-of-study visit will conclude the trial, where final assessments will be conducted to gather comprehensive data on the bioequivalence of the drug formulations.

The expected length of participant involvement will span the duration of the trial, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include non-compliance with the study protocol, adverse events, or withdrawal of consent by the participant. The trial is structured to ensure rigorous data collection and analysis, contributing to the understanding of the bioequivalence of the fixed-dose combination therapy.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is intended for pediatric use or if it is classified as an orphan drug. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments, including their names, dosages, or administration routes. The trial documentation does not specify any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring.

Due to the lack of specific information in the provided data, further details regarding the experimental and non-experimental treatments, as well as their administration and monitoring, are not available. The trial documentation should be consulted for comprehensive information on the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy within the framework of a Phase 2 study. The trial is scheduled to commence recruitment on December 8, 2025, with an estimated completion date of March 3, 2026. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will adhere to standard protocols for data collection and analysis, ensuring that all efficacy-related data is systematically gathered and evaluated. The study will follow a structured timeline, with assessments likely occurring at various timepoints throughout the trial duration, although these specific timepoints are not provided. The trial will utilize appropriate tools and instruments to ensure the accuracy and reliability of efficacy measurements, in line with the scientific rigor expected in clinical research.